Hanmi Pharm Signs Exclusive Licensing Deal with Genentech for Novel Obesity Therapy

Contributed by: PR Newswire

Images

PR Newswire associated0

Tags

Hanmi-Genentech

More Like This

PR Newswire associated0

Hanmi Unveils Novel Obesity Drug 'HM17321' : A Game-Changer in Overcoming GLP-1-Associated Muscle Loss

PR Newswire associated0

Hanmi Signs Licensing Deal with Lilly for sonefpeglutide (LAPSGLP-2 analog)

PR Newswire associated0

Health Hope Pharma Enters into Exclusive Licensing Agreement with Gilead Sciences

PR Newswire associated0

China Innovative Drug NHWD-870 Receives Breakthrough Therapy Designation, Bringing New Hope of Survival to NUT Carcinoma Patients

PR Newswire associated0

Hanmi's Oral Delivery Platform Compound Licensed to Gilead

HUADONG MEDICINE Announces Positive Phase I Results for Innovative Oral Small Molecule GLP-1 Receptor Agonist HDM1002

PR Newswire associated0

Eccogene Enters Exclusive License Agreement With AstraZeneca to Develop and Commercialize Small Molecule GLP-1 Receptor Agonist ECC5004 for Cardiometabolic Diseases

PR Newswire associated0

Hanmi Pharmaceutical and Beijing Hanmi Progress Clinical Trials of Co-developed BH3120 as a Next-Generation Cancer Immunotherapy